STRO Quote, Financials, Valuation and Earnings

Daré Bioscience, Inc. has a net margin of -586.58% compared to Sutro Biopharma, Inc.'s net margin of -154904.35%. Sutro Biopharma, Inc.'s return on equity of -10195.04% beat Daré Bioscience, Inc.'s return on equity of --.

Sutro Biopharma, Inc. has a consensus price target of $22.43, signalling upside risk potential of 124.74%. On the other hand Daré Bioscience, Inc. has an analysts' consensus of $10.75 which suggests that it could grow by 414.35%. Given that Daré Bioscience, Inc. has higher upside potential than Sutro Biopharma, Inc., analysts believe Daré Bioscience, Inc. is more attractive than Sutro Biopharma, Inc..

Sutro Biopharma, Inc. has a beta of 1.615, which suggesting that the stock is 61.536% more volatile than S&P 500. In comparison Daré Bioscience, Inc. has a beta of 0.771, suggesting its less volatile than the S&P 500 by 22.917%.

Sutro Biopharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Daré Bioscience, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sutro Biopharma, Inc. pays -- of its earnings as a dividend. Daré Bioscience, Inc. pays out -- of its earnings as a dividend.

Sutro Biopharma, Inc. quarterly revenues are $9.7M, which are larger than Daré Bioscience, Inc. quarterly revenues of $2.3K. Sutro Biopharma, Inc.'s net income of -$56.9M is lower than Daré Bioscience, Inc.'s net income of -$3.6M. Notably, Sutro Biopharma, Inc.'s price-to-earnings ratio is -- while Daré Bioscience, Inc.'s PE ratio is 95.38x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sutro Biopharma, Inc. is 2.56x versus 421.90x for Daré Bioscience, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

GT Biopharma, Inc. has a net margin of -586.58% compared to Sutro Biopharma, Inc.'s net margin of --. Sutro Biopharma, Inc.'s return on equity of -10195.04% beat GT Biopharma, Inc.'s return on equity of -626.24%.

Sutro Biopharma, Inc. has a consensus price target of $22.43, signalling upside risk potential of 124.74%. On the other hand GT Biopharma, Inc. has an analysts' consensus of $8.00 which suggests that it could grow by 956.94%. Given that GT Biopharma, Inc. has higher upside potential than Sutro Biopharma, Inc., analysts believe GT Biopharma, Inc. is more attractive than Sutro Biopharma, Inc..

Sutro Biopharma, Inc. has a beta of 1.615, which suggesting that the stock is 61.536% more volatile than S&P 500. In comparison GT Biopharma, Inc. has a beta of 1.524, suggesting its more volatile than the S&P 500 by 52.367%.

Sutro Biopharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. GT Biopharma, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sutro Biopharma, Inc. pays -- of its earnings as a dividend. GT Biopharma, Inc. pays out -- of its earnings as a dividend.

Sutro Biopharma, Inc. quarterly revenues are $9.7M, which are larger than GT Biopharma, Inc. quarterly revenues of --. Sutro Biopharma, Inc.'s net income of -$56.9M is lower than GT Biopharma, Inc.'s net income of -$3.1M. Notably, Sutro Biopharma, Inc.'s price-to-earnings ratio is -- while GT Biopharma, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sutro Biopharma, Inc. is 2.56x versus 59.35x for GT Biopharma, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals, Inc. has a net margin of -586.58% compared to Sutro Biopharma, Inc.'s net margin of -255.85%. Sutro Biopharma, Inc.'s return on equity of -10195.04% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.

Sutro Biopharma, Inc. has a consensus price target of $22.43, signalling upside risk potential of 124.74%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -83.96%. Given that Sutro Biopharma, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Sutro Biopharma, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..

Sutro Biopharma, Inc. has a beta of 1.615, which suggesting that the stock is 61.536% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.

Sutro Biopharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Sutro Biopharma, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Sutro Biopharma, Inc. quarterly revenues are $9.7M, which are larger than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Sutro Biopharma, Inc.'s net income of -$56.9M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Sutro Biopharma, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 8.90x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sutro Biopharma, Inc. is 2.56x versus 10.30x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Syndax Pharmaceuticals, Inc. has a net margin of -586.58% compared to Sutro Biopharma, Inc.'s net margin of -132.36%. Sutro Biopharma, Inc.'s return on equity of -10195.04% beat Syndax Pharmaceuticals, Inc.'s return on equity of -136.36%.

Sutro Biopharma, Inc. has a consensus price target of $22.43, signalling upside risk potential of 124.74%. On the other hand Syndax Pharmaceuticals, Inc. has an analysts' consensus of $39.31 which suggests that it could grow by 89.25%. Given that Sutro Biopharma, Inc. has higher upside potential than Syndax Pharmaceuticals, Inc., analysts believe Sutro Biopharma, Inc. is more attractive than Syndax Pharmaceuticals, Inc..

Sutro Biopharma, Inc. has a beta of 1.615, which suggesting that the stock is 61.536% more volatile than S&P 500. In comparison Syndax Pharmaceuticals, Inc. has a beta of 0.476, suggesting its less volatile than the S&P 500 by 52.361%.

Sutro Biopharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Syndax Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sutro Biopharma, Inc. pays -- of its earnings as a dividend. Syndax Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Sutro Biopharma, Inc. quarterly revenues are $9.7M, which are smaller than Syndax Pharmaceuticals, Inc. quarterly revenues of $45.9M. Sutro Biopharma, Inc.'s net income of -$56.9M is higher than Syndax Pharmaceuticals, Inc.'s net income of -$60.7M. Notably, Sutro Biopharma, Inc.'s price-to-earnings ratio is -- while Syndax Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sutro Biopharma, Inc. is 2.56x versus 16.06x for Syndax Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.